Drug or treatment

Pucotenlimab clinical trials

• 22Clinical trials
• 2New in 30 days
• 2Countries

Newest trials

All recruiting trials (22)

• Pucotenlimab and Anlotinib with Chemo Before Surgery for Early-Stage Triple-Negative Breast Cancer

  This study tests a combo of pucotenlimab, anlotinib, and nab-paclitaxel before surgery in adults with newly diagnosed, stage II-III triple-negative breast cancer that is PD-L1 known.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou · NCT07896668

• Becotatug Vedotin plus Pucotenlimab for EGFR-positive metastatic colorectal cancer

  This study tests whether combining becotatug vedotin with pucotenlimab can shrink tumors in adults with colorectal cancer that has returned or spread after at least two prior treatments and whose tumors express EGFR.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07884188

• Triple-drug neoadjuvant therapy for EGFR-positive locally advanced head and neck cancer

  This trial tests a three-drug neoadjuvant regimen (Becotatug Vedotin, Pucotenlimab, and Cisplatin) in adults with EGFR-positive, locally advanced head and neck cancer to see if it can shrink tumors before surgery or chemoradiotherapy.

  Recruiting at 2 sites Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 1 other locations · NCT07814287

• Combo of tunlametinib, pucotenlimab, and hydroxychloroquine in NRAS-mutant melanoma

  This study tests whether adding hydroxychloroquine to tunlametinib and pucotenlimab helps people with NRAS-mutant melanoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07750067

• Becotatug Vedotin Plus Pucotenlimab in EGFR-High Advanced Cancers

  This phase II study tests whether combining Becotatug Vedotin with Pucotenlimab helps people whose advanced solid tumors express high EGFR.

  Recruiting Phase 2 Tianjin Medical University Second Hospital · Tianjin, Tianjin Municipality · NCT07712029

• Neoadjuvant EGFR-ADC plus anti-PD-1 therapy for resectable locally advanced hypopharyngeal cancer

  This trial tests whether a targeted EGFR-ADC drug plus an anti-PD-1 antibody given before surgery can improve outcomes for adults with resectable locally advanced hypopharyngeal squamous cell carcinoma.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07665190

• Becotatug Vedotin plus Pucotenlimab before and after surgery for locally recurrent head and neck cancer

  This trial tests whether adding Becotatug Vedotin and Pucotenlimab around surgery helps patients with locally recurrent resectable head and neck squamous cell carcinoma improve outcomes.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07632339

• Pucotenlimab plus Becotatug Vedotin in locally advanced resectable head and neck cancer

  This study tests whether giving Pucotenlimab with Becotatug Vedotin around surgery helps patients with resectable head and neck squamous cell carcinoma.

  Recruiting Phase 2 Lepu Biopharma Co., Ltd. · Beijing, Beijing Municipality and 14 other locations · NCT07586124

• Neoadjuvant CAPOX chemotherapy with or without pucotenlimab plus selective short-course radiotherapy for locally advanced rectal cancer

  This trial tests whether adding the immunotherapy drug pucotenlimab to CAPOX chemotherapy, with selective short-course radiotherapy if needed, helps people with pMMR/MSS locally advanced rectal cancer shrink their tumors before surgery.

  Recruiting Phase 3 Sun Yat-sen University · Guangzhou, Guangdong · NCT07528209

• EGFR-targeted therapy plus PD-1 blocker before surgery for advanced penile cancer

  This phase II trial tests whether Becotatug vedotin plus Pucotenlimab given before surgery can shrink tumors in men with advanced penile cancer and help preserve the penis when possible.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT07518979

• Beocotatug Vedotin plus Pucotenlimab for EGFR-positive advanced penile cancer

  This trial tests whether a targeted antibody-drug conjugate plus a PD-1 inhibitor can help people with EGFR-positive advanced penile cancer who have limited or no chemotherapy options.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07497919

• Low-dose radiotherapy with pucotenlimab and CAPEOX for pMMR locally advanced rectal cancer

  This trial will try adding a single low dose of radiotherapy to the immunotherapy drug pucotenlimab plus CAPEOX chemotherapy before surgery to see if it improves tumor response in people with pMMR/MSS locally advanced rectal cancer.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guanggong · NCT07448142

• Pucotenlimab plus vorolanib before surgery for clear cell kidney cancer

  This trial tests whether giving pucotenlimab with vorolanib before surgery can shrink localized clear cell kidney tumors and make kidney-sparing surgery easier for adults with difficult-to-remove tumors.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Other (Non U.s.) · NCT07386158

• Low-dose local radiotherapy plus pucotenlimab with standard chemotherapy for advanced pancreatic cancer

  This trial tests whether adding low-dose local radiation and the PD-1 blocker pucotenlimab to standard chemotherapy can help people with advanced, unresectable pancreatic cancer.

  Recruiting Phase 1/2 Zhejiang Provincial People's Hospital · Hangzhou, Zhejiang · NCT07312422

• MRG003 plus pucotenlimab for EGFR-positive advanced anaplastic or poorly differentiated thyroid cancer

  This trial will see if combining MRG003 and pucotenlimab can help adults with EGFR-positive unresectable or metastatic anaplastic or poorly differentiated thyroid cancer by shrinking tumors or slowing their growth.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07235566

• Sacituzumab tirumotecan plus pucotenlimab for advanced cholangiocarcinoma

  This trial will test whether combining sacituzumab tirumotecan with pucotenlimab can help people with unresectable or metastatic cholangiocarcinoma.

  Recruiting Phase 2 Sir Run Run Shaw Hospital · Hangzhou, Zhejiang · NCT07105852

• MRG003 plus pucotenlimab versus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma

  This trial tests whether combining MRG003 with pucotenlimab works better than standard chemotherapy for people with recurrent or metastatic nasopharyngeal carcinoma who have had at least one prior systemic treatment.

  Recruiting Phase 3 Lepu Biopharma Co., Ltd. · Guangzhou, Guangdong · NCT06976190

• Evaluating Pucotenlimab for treating pediatric lymphoepithelioma-like carcinoma

  This study is testing a new treatment combining pucotenlimab with chemotherapy to see if it helps children and teenagers with a rare type of cancer called lymphoepithelioma-like carcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06969534

• MRG003 alone or with the PD‑1 drug pucotenlimab before chemoradiotherapy for locally advanced head and neck squamous cell carcinoma

  This trial will test whether giving MRG003 alone or together with the PD‑1 drug pucotenlimab before standard chemoradiotherapy helps people with locally advanced head and neck squamous cell carcinoma.

  Recruiting Phase 2 Groupe Oncologie Radiotherapie Tete et Cou · Villejuif · NCT06959108

• Pucotenlimab with radiation and chemotherapy before surgery for locally advanced rectal cancer

  We will test whether adding the PD-1 drug pucotenlimab to standard pre-surgery chemoradiation helps people with locally advanced rectal cancer have better tumor responses.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06770270

• Combining Pucotenlimab with standard chemotherapy for pediatric rhabdomyosarcoma

  This study is testing if adding a new drug called Pucotenlimab to standard chemotherapy can help children and teens with a type of cancer called rhabdomyosarcoma.

  Recruiting Phase 1/2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06456892

• Combination therapy for patients with unresectable intrahepatic cholangiocarcinoma

  This study is testing a new combination of chemotherapy and targeted therapy to see if it can shrink tumors in patients with a type of liver cancer that can't be surgically removed.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT06192797

Quick answers

How many clinical trials of Pucotenlimab are recruiting right now?

22, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in China (21 trials), France (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 18, Phase 1/2: 2, Phase 3: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →